澳大利亚痛风与高尿酸血症患病率:一项更新的系统综述
该研究系统检索2011年5月至2020年6月发表的文献,纳入12篇分析痛风患病率、4篇分析高尿酸血症患病率。自报痛风诊断的研究患病率为4.5%–6.8%,采用电子编码或废水估算的研究成人患病率为1.5%–2.9%;高尿酸血症患病率为10.5%–16.6%。作者认为澳大利亚痛风患病率高于全球比较且随时间增加。
要点
- 自报痛风诊断的患病率为4.5%–6.8%,电子编码或废水估算的成人患病率为1.5%–2.9%。
- 高尿酸血症在 Caucasian 或澳大利亚代表性人群中患病率为10.5%–16.6%。
- 患病率随年龄、男性性别及时间增加,与全球数据一致。
核心结论
- 与全球比较,澳大利亚痛风患病率高且随时间持续增加,高尿酸血症患病率也高但当代数据有限。
研究设计与样本
- 系统综述,检索 MEDLINE、Embase、Web of Science 及相关网站,纳入2011年5月至2020年6月发表的文献。
- 筛查118篇全文,12篇纳入痛风患病率分析,4篇纳入高尿酸血症分析。
主要发现
- 采用自报痛风诊断定义的研究,患病率在4.5%至6.8%之间。
- 采用全科医生电子编码数据或废水估算别嘌醇消耗的研究,成人患病率在1.5%至2.9%之间。
- 高尿酸血症在 Caucasian 或澳大利亚代表性人群中患病率在10.5%至16.6%之间。
- 患病率随年龄增长、男性性别及时间推移而增加,与全球数据一致。
关键数值与推荐
- AIHW 报告的患病率为0.8%,作者认为与其他已发表研究不一致。
- AIHW 估算将慢性病状态(当前且已持续或预计持续超过六个月)应用于澳大利亚国家健康调查中的痛风病例,可能导致患病率低估。
临床怎么用
- 临床需注意澳大利亚痛风及高尿酸血症实际患病率可能高于 AIHW 报告的0.8%,应结合研究设计差异解读流行病学数据。
局限性
- 患病率数据变异大,主要归因于研究设计和样本年龄范围不同。
- 高尿酸血症的当代数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gout continues to increase in prevalence in developed countries with Oceanic countries particularly affected. Both gout and hyperuricaemia are associated with the metabolic syndrome and its sequelae. Recently, the Australian Institute for Health and Welfare (AIHW) reported a prevalence rate of 0.8% which appeared incongruous with other published research. Thus, an updated systematic review was undertaken to review the literature on the prevalence of gout and hyperuricaemia in Australia from data published after 2011. METHODS: A comprehensive, systematic search was conducted in MEDLINE, Embase and Web of Science in addition to relevant websites to identify research reporting the prevalence of gout and/or hyperuricaemia in Australia from May 2011 until June 2020. Crude gout and hyperuricaemia prevalence data was obtained and presented alongside case ascertainment, time-period, age range and stratified by gender if available. RESULTS: 118 full text articles were screened. 12 articles were included for analysis of gout prevalence. 4 articles were identified for the hyperuricaemia analysis. Wide variation in prevalence figures exist largely due study design and sample age range. Studies using a case definition of self-reported diagnosis of gout reported prevalence rates between 4.5% and 6.8%. The remaining studies used either electronic coding data from general practitioners or wastewater estimation of allopurinol consumption and documented adult prevalence rates between 1.5% and 2.9%. Prevalence increases with age, male sex and over time in keeping with global data. Hyperuricaemia prevalence ranged between 10.5% and 16.6% in Caucasian or an Australian representative population. AIHW estimates applied a chronic condition status, defined as current and lasted or expected to last more than six months, to cases of gout in the Australian National Health Survey. This likely results in an under-estimation in reported Australian gout prevalence rates. CONCLUSIONS: Gout is highly prevalent in Australia compared to global comparisons and continues to increase over time. Hyperuricaemia prevalence is also high although contemporary data is limited.
引用
- Pathmanathan K, Robinson PC, Hill CL, et al. The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. Semin Arthritis Rheum. 2020. PMID: 33360648. doi:10.1016/j.semarthrit.2020.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。